.png){kind=icon}
Covid-19：商业化和报销
Incorporate market access and Phase IV solutions into your COVID-19 program strategy. We offer comprehensive real-world safety, efficacy and patient access provision for post- and peri-approval studies.
Late-phase and commercialization activities are complex and require informed strategies to maximize your product’s clinical and commercial value. Together we can help you over come the unique challenges as you prepare to launch and commercialize your COVID-19 product, ensuring that patients have access to safe and effective treatments.
Generate evidence, communicate the value and expedite patient access
一旦一个可行的COVID-19对疫苗或治疗s the market, it is essential to convert the scientific and therapeutic advances to improved outcomes by communicating its value to payers and physicians, while navigating reimbursement challenges thatfacilitate fast accessto patients and payers.
企业连续性规划在患者支持方案中的重要性
评估您当前和未来的报销呼叫中心策略并不是太早，并尽可能为中断患者访问您的Covid-19治疗的意外事件。
Monitor the ongoing safety and efficacy of your COVID-19 vaccine or therapy
Plan your patient safety journey from clinical trials to post-marketing to ensure patient safety and regulatory compliance, while improving quality and data integrity and gain valuable insights about your safety and药物事件业务。
主动计划履行您的批准后Covid-19承诺
As your partner, we can optimize patient support, adherence and product access by leveraging real-world evidence (RWE) and innovative Phase IV studies to demonstrate value, efficacy and safety of your COVID-19 product to payers, prescribers and regulatory bodies, as well as provide you with a world-leading safety solutions portfolio.
- 成功收集RWE并延长化合物的价值
- 加强您的市场地位和支持
- 填补登记要求与战略后期研究设计之间的差距
- Engage with patients in meaningful ways and through patient-reported outcomes (PROs)
按需网络研讨会：Covid-19时代的疫苗创新：大流行速度的安全
Moderated by: Jerome Premmereur, VP Patient Safety Solutions & Adjudication, Covance
Summary:
在全世界危机的这段时间内，对Covid-19的疫苗接种的加速需求越来越大。无论基因组和分子生物学的最新进步如何，可行的疫苗批准仍可能超过一年。该网络研讨会将讨论“流行速度”疫苗批准周围的挑战和安全问题。
Podcast: Drug Adverse Event Reporting During COVID-19 Lockdown
Featuring: Dr. Thomas Leigh
Summary:
一个播客，成为托马斯·雷博士，董事会患者安全解决方案和审判的医疗小组主任托马斯·雷博士 - 全球Covid-19大流行为临床试验和消费者报告药物不良事件带来了新的紧迫性和挑战市场。在未来几个月的情况下，我们可以了解在锁上期间发生的不良事件但仅在稍后阶段报告的不良事件。大流行和其效果是重要的，对于我们所有人参与评估药物安全性的人来说，要注意安全事件的证据，这可能是非常重要的，这可能是之前没有以前的光明。
与我们的Covid-19响应团队联系
接触Us
Labcorp的Covance是一家领先的全球生命科学公司，为药物，医疗器械和诊断，作物保护和化学工业提供合同研究服务。
COVANCE is a registered trademark and the marketing name for Covance Inc. and its subsidiaries around the world.